A document related to the project entitled Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation is now available for feedback from all interested stakeholders.
Call for Feedback
Feedback Due By
Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
CADTH has received the following notice(s) of pending drug submission(s).
halobetasol propionate and tazarotene
Bausch Health, Canada Inc.
Psoriasis, moderate to severe plaque
Call for patient input
Patient input deadline
Submit patient input
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.
See Pharmaceutical Reviews Update – Issue 4 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:
an upcoming webinar on the CADTH/pCODR clinician input and feedback process
an update on the transition of the Cancer Drug Implementation Advisory Committee work
a reminder about pre-submissio...